Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The pharmacokinetics of oxypurinol in people with gout.

Stocker SL, McLachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, Day RO.

Br J Clin Pharmacol. 2012 Sep;74(3):477-89. doi: 10.1111/j.1365-2125.2012.04207.x.

2.

The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.

Wright DF, Stamp LK, Merriman TR, Barclay ML, Duffull SB, Holford NH.

Eur J Clin Pharmacol. 2013 Jul;69(7):1411-21. doi: 10.1007/s00228-013-1478-8. Epub 2013 Mar 10.

PMID:
23475133
3.

A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis.

Wright DF, Doogue MP, Barclay ML, Chapman PT, Cross NB, Irvine JH, Stamp LK.

Eur J Clin Pharmacol. 2017 Jan;73(1):71-78. doi: 10.1007/s00228-016-2133-y. Epub 2016 Sep 28.

PMID:
27683090
4.

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM.

Clin Pharmacokinet. 2007;46(8):623-44. Review.

PMID:
17655371
5.

Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.

Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.

Clin Pharmacol Ther. 2011 Sep;90(3):392-8. doi: 10.1038/clpt.2011.113. Epub 2011 Jul 27.

PMID:
21796116
6.

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.

Panomvana D, Sripradit S, Angthararak S.

J Clin Rheumatol. 2008 Feb;14(1):6-11. doi: 10.1097/RHU.0b013e318164dceb.

PMID:
18431090
7.

Predicting allopurinol response in patients with gout.

Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK.

Br J Clin Pharmacol. 2016 Feb;81(2):277-89. doi: 10.1111/bcp.12799. Epub 2015 Dec 29.

8.

Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.

Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.

Rheumatology (Oxford). 2012 Sep;51(9):1670-6. doi: 10.1093/rheumatology/kes091. Epub 2012 Apr 26.

PMID:
22539486
9.

An audit of a therapeutic drug monitoring service for allopurinol therapy.

Kannangara DR, Ramasamy SN, Ray JE, Jones G, Graham GG, Williams KM, Day RO.

Ther Drug Monit. 2013 Dec;35(6):863-6. doi: 10.1097/FTD.0b013e318299920a.

PMID:
24263644
10.

The optimal use of allopurinol: an audit of allopurinol use in South Auckland.

Stamp L, Gow P, Sharples K, Raill B.

Aust N Z J Med. 2000 Oct;30(5):567-72.

PMID:
11108066
11.

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.

Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO.

J Rheumatol. 2011 May;38(5):904-10. doi: 10.3899/jrheum.101160. Epub 2011 Feb 1.

PMID:
21285173
12.

[Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].

Ohno I, Okabe H, Yamaguchi Y, Saikawa H, Uetake D, Hikita M, Gomi H, Ichida K, Hosoya T.

Nihon Jinzo Gakkai Shi. 2008;50(4):506-12. Japanese.

PMID:
18546882
13.

Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.

Ng DY, Stocker SL, Graham GG, Williams KM, Day RO.

Eur J Clin Pharmacol. 2011 Jul;67(7):709-13. doi: 10.1007/s00228-010-0963-6. Epub 2010 Dec 23.

PMID:
21181139
14.

Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.

Keith MP, Gilliland WR.

Clin Pharmacol Ther. 2011 Sep;90(3):363-4. doi: 10.1038/clpt.2011.146.

PMID:
21862966
15.
16.

Determination of allopurinol and oxypurinol in human plasma and urine by liquid chromatography-tandem mass spectrometry.

Liu X, Ni XJ, Shang DW, Zhang M, Hu JQ, Qiu C, Luo FT, Wen YG.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 15;941:10-6. doi: 10.1016/j.jchromb.2013.09.028. Epub 2013 Oct 1.

PMID:
24184830
17.

Renal excretions of oxypurinol and oxypurines--effects of pyrazinamide, probenecid and benzbromarone.

Yamamoto T, Moriwaki Y, Takahashi S, Hada T, Higashino K.

Adv Exp Med Biol. 1989;253A:277-81. No abstract available.

PMID:
2624203
18.

Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin.

Chung WH, Chang WC, Stocker SL, Juo CG, Graham GG, Lee MH, Williams KM, Tian YC, Juan KC, Jan Wu YJ, Yang CH, Chang CJ, Lin YJ, Day RO, Hung SI.

Ann Rheum Dis. 2015 Dec;74(12):2157-64. doi: 10.1136/annrheumdis-2014-205577. Epub 2014 Aug 12.

PMID:
25115449
19.

Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.

Stamp LK, Merriman TR, Barclay ML, Singh JA, Roberts RL, Wright DF, Dalbeth N.

Semin Arthritis Rheum. 2014 Oct;44(2):170-4. doi: 10.1016/j.semarthrit.2014.05.007. Epub 2014 May 9. Review.

20.

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Stocker SL, Williams KM, McLachlan AJ, Graham GG, Day RO.

Clin Pharmacokinet. 2008;47(2):111-8.

PMID:
18193917

Supplemental Content

Support Center